330 related articles for article (PubMed ID: 22508650)
1. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
[TBL] [Abstract][Full Text] [Related]
2. Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function.
Yuan X; Koehn J; Hogge DE
Leuk Res; 2015 Jul; 39(7):689-95. PubMed ID: 26002514
[TBL] [Abstract][Full Text] [Related]
3. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
Benderra Z; Faussat AM; Sayada L; Perrot JY; Chaoui D; Marie JP; Legrand O
Clin Cancer Res; 2004 Dec; 10(23):7896-902. PubMed ID: 15585622
[TBL] [Abstract][Full Text] [Related]
5. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
7. Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia.
van der Pol MA; Broxterman HJ; Pater JM; Feller N; van der Maas M; Weijers GW; Scheffer GL; Allen JD; Scheper RJ; van Loevezijn A; Ossenkoppele GJ; Schuurhuis GJ
Haematologica; 2003 Feb; 88(2):134-47. PubMed ID: 12604403
[TBL] [Abstract][Full Text] [Related]
8. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
[TBL] [Abstract][Full Text] [Related]
10. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
11. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia.
Raaijmakers MH; de Grouw EP; Heuver LH; van der Reijden BA; Jansen JH; Scheper RJ; Scheffer GL; de Witte TJ; Raymakers RA
Clin Cancer Res; 2005 Mar; 11(6):2436-44. PubMed ID: 15788695
[TBL] [Abstract][Full Text] [Related]
14. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
[TBL] [Abstract][Full Text] [Related]
15. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
16. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; Espinoza-Delgado I; Ross DD
Clin Cancer Res; 2013 Apr; 19(7):1838-51. PubMed ID: 23403629
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
18. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
[TBL] [Abstract][Full Text] [Related]
20. Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia.
Burcu M; O'Loughlin KL; Ford LA; Baer MR
Leukemia; 2008 Nov; 22(11):2110-5. PubMed ID: 18418409
[No Abstract] [Full Text] [Related]
[Next] [New Search]
